Daily Trades
- Dylan Jovine
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
Thirty years of investing has taught me that when it’s time to sell, it’s time to sell. There’s no point in crying about it.
- Dylan Jovine
In April, we sold half of our shares in Apellis Pharmaceuticals, Inc (SYM: APLS) at $85, a 76% increase from our recommended price of $48.42.
- Dylan Jovine
Let's start by closing out one of our older positions for a small profit.
- Dylan Jovine
I recommend selling half your shares in Apellis Pharmaceuticals, Inc (SYM: APLS)
- Dylan Jovine
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
- Dylan Jovine
A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
- Dylan Jovine
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
deal of the month
Categories
The Empire Strikes Back: DOJ's Latest Move Against Apple
What Supporting Ukraine ACTUALLY Means for your Retirement Account
What Our Loss in Spirit Airlines Taught Me
Recent posts
Tags
Connect with Us
- Dylan Jovine
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
Thirty years of investing has taught me that when it’s time to sell, it’s time to sell. There’s no point in crying about it.
- Dylan Jovine
In April, we sold half of our shares in Apellis Pharmaceuticals, Inc (SYM: APLS) at $85, a 76% increase from our recommended price of $48.42.
- Dylan Jovine
Let's start by closing out one of our older positions for a small profit.
- Dylan Jovine
I recommend selling half your shares in Apellis Pharmaceuticals, Inc (SYM: APLS)
- Dylan Jovine
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
- Dylan Jovine
A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
- Dylan Jovine
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.